Trial Profile
A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Revusiran (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 15 Mar 2015 Results presented at the American College of Cardiology (ACC) Annual Scientific Session 2015, according to Alnylam Pharmaceuticals media release.
- 15 Mar 2015 Results published in the Media Release.
- 25 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.